Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pirfenidone: A Novel Anti-Scarring Therapy for Diabetic Nephropathy.

Trial Profile

Pirfenidone: A Novel Anti-Scarring Therapy for Diabetic Nephropathy.

Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Pirfenidone (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Jun 2011 Results published in the Journal of the American Society of Nephrology.
    • 10 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top